Immunomodulating Agents as Antipruritics - 19/06/18

Riassunto |
Chronic pruritus, or itch lasting greater than 6 weeks, is an increasingly common and debilitating medical problem. Recent studies have unveiled previously unrecognized neuroimmune axes whereby inflammatory cytokines act directly on the nervous system to promote itch. Thus, the emergence of newer targeted biologic therapies has generated the possibility of novel treatment strategies for chronic itch disorders. This article reviews the pathophysiology of multiple chronic itch disorders, including atopic dermatitis, chronic idiopathic pruritus, chronic urticaria, and prurigo nodularis. Furthermore, new and emerging immunomodulatory therapies that will likely alter current treatment paradigms are discussed.
Il testo completo di questo articolo è disponibile in PDF.Keywords : Itch, Pruritus, Immunomodulator, Atopic dermatitis, Urticaria, Prurigo nodularis, Chronic idiopathic pruritus
Mappa
| Disclosure Statement: B.S. Kim has served on advisory boards for Celgene, Regeneron, and Sanofi. He has worked as a consultant for Incyte and has received support for research from Celgene and LEO Pharma. S. Erickson, Z. Nahmias, and I.S. Rosman have nothing to disclose. |
Vol 36 - N° 3
P. 325-334 - luglio 2018 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?
